Min Soo Kim
Lars Plate lab
Cystic fibrosis (CF) is one of the most prevalent lethal genetic disease that has over 2000 identified genetic variants in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. The vast array of protein interactions with the proteostasis network that vary from mutation to mutation greatly complicate the streamlining of viable treatment methods. A novel CFTR corrector molecule Elexacaftor (VX-445) was recently FDA approved for use in patients with the most common CF causing mutation, ΔF508. My project aims to uncover the interactions between the proteostasis network and CFTR variants in response to VX-445 correction via affinity purification mass spectrometry.